Добірка наукової літератури з теми "Hepatitis viruses Prevention"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Hepatitis viruses Prevention".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Hepatitis viruses Prevention"
Kayesh, Mohammad Enamul Hoque, Michinori Kohara, and Kyoko Tsukiyama-Kohara. "Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview." Microorganisms 10, no. 11 (November 15, 2022): 2266. http://dx.doi.org/10.3390/microorganisms10112266.
Повний текст джерелаRobertson, Betty H., and Wendi L. Kuhnert. "Hepatitis Viruses—Prevention and Control in the Laboratory Setting." Applied Biosafety 8, no. 1 (March 2003): 6–13. http://dx.doi.org/10.1177/153567600300800102.
Повний текст джерелаFry, Donald E. "Hepatitis: Risks for the Surgeon." American Surgeon 66, no. 2 (February 2000): 178–83. http://dx.doi.org/10.1177/000313480006600214.
Повний текст джерелаVelebit, B. "Foodborne viruses — an emerging pathogens." Theory and practice of meat processing 5, no. 4 (December 29, 2020): 18–22. http://dx.doi.org/10.21323/2414-438x-2020-5-4-18-22.
Повний текст джерелаBullington, Brooke W., Katherine Klemperer, Keith Mages, Andrea Chalem, Humphrey D. Mazigo, John Changalucha, Saidi Kapiga, Peter F. Wright, Maria M. Yazdanbakhsh, and Jennifer A. Downs. "Effects of schistosomes on host anti-viral immune response and the acquisition, virulence, and prevention of viral infections: A systematic review." PLOS Pathogens 17, no. 5 (May 20, 2021): e1009555. http://dx.doi.org/10.1371/journal.ppat.1009555.
Повний текст джерелаQədir qızı Əbilova, Rübayə, Gülnarə Alışa qızı Cəfərova, and Hafiz Maarif oğlu Osmanov. "The role of viruses and bacteria in the development of cancer." NATURE AND SCIENCE 11, no. 06 (August 23, 2021): 5–10. http://dx.doi.org/10.36719/2707-1146/11/5-10.
Повний текст джерелаTaylor, John M. "Infection by Hepatitis Delta Virus." Viruses 12, no. 6 (June 16, 2020): 648. http://dx.doi.org/10.3390/v12060648.
Повний текст джерелаLarin, V. F., L. I. Zhukova, V. V. Lebedev, and G. K. Rafeyenko. "INTERFERENCE INTERACTION OF VIRUSES IN THE REGULATION OF AN EPIDEMIC PROCESS." Epidemiology and Infectious Diseases 17, no. 1 (February 15, 2012): 25–29. http://dx.doi.org/10.17816/eid40639.
Повний текст джерелаVenkateswarlu, Devarakonda, Burri T. Rao, Devarakonda Manasa, and Ravi Y. Chowdhary. "An assessment of knowledge and awareness on hepatitis B and hepatitis C viruses among police trainees attending police training college, Ongole, Prakasam District, Andhra Pradesh, India." International Journal Of Community Medicine And Public Health 8, no. 10 (September 27, 2021): 5006. http://dx.doi.org/10.18203/2394-6040.ijcmph20213811.
Повний текст джерелаSadlier, Corinna, Keeva Madden, Sean O’Gorman, Brendan Crowley, and Colm Bergin. "Development of chronic hepatitis B infection in a hepatitis B vaccine responder." International Journal of STD & AIDS 28, no. 5 (November 12, 2016): 526–28. http://dx.doi.org/10.1177/0956462416674835.
Повний текст джерелаДисертації з теми "Hepatitis viruses Prevention"
Fye, Haddy K. S. "Protein profiling for hepatocellular carcinoma biomarker discovery in West African subjects." Thesis, University of Oxford, 2013. http://ora.ox.ac.uk/objects/uuid:8b9cddda-5c65-45f0-9354-9343c317bef6.
Повний текст джерелаSangfelt, Per. "Prevention and treatment of hepatitis B virus infection /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-301-9/.
Повний текст джерелаYuen, Man-fung, and 袁孟峰. "Chronic hepatitis B virus infection in the Chinese: natural history, sequelae, treatment and prevention." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2000. http://hub.hku.hk/bib/B2333177X.
Повний текст джерелаMachiya, Tichaona. "Knowledge, attitudes and practices of healthcare workers at the Princess Marina Hospital in Botswana, regarding hepatitis B prevention and control." Thesis, University of Limpopo (Medunsa Campus), 2011. http://hdl.handle.net/10386/457.
Повний текст джерелаIntroduction: Hepatitis B virus (HBV) is a highly infectious virus responsible for considerable morbidity and mortality world wide. Chronic HBV carriers can transmit HBV parenterally in a hospital setting putting healthcare workers (HCWs) and their patients at risk of infection. Aim and objectives: This study aimed to investigate knowledge, attitudes and practices towards prevention and control of HBV amongst nurses, doctors and laboratory personnel. Objectives were to determine: (a) the knowledge; (b) the attitudes; (c) the practices of nurses, doctors and laboratory personnel; (d) if there are any associations between (1) knowledge and practice, and (2) attitudes and practice; (e) the predictors of HBV vaccination uptake. Materials and Methods: This was a cross-sectional descriptive study. Self-administered questionnaires were distributed to doctors, laboratory staff and nurses at Princess Marina Hospital. Results: Two hundred questionnaires were distributed and a total of 117 were returned, giving an overall response rate of 58.5%. More doctors had good knowledge (38.9% [7/18]), followed by 20% (4/20) of laboratory staff and 11.4% (9/79) of nurses. Most staff (100% [20/20] of laboratory staff; 97.5% [77/79] of nurses; 94.4% [17/18] of doctors) had positive attitudes. More laboratory staff (100 [20/20]) displayed good practices, followed by nurses (94.9% [75/79]); and lastly doctors (88.9% [16/18]). There were no significant associations between knowledge or attitudes and practices. Vaccination was inadequate, with 50.9% (59/116) of HCWs having received at least one dose, and of these only 61% (36/59) receiving all 3 doses. Needle stick injuries occurred in 31.6% (37/117), while 33.9% (39/115) reported blood or body fluid splashes. None of the HCWs accessed PEP after exposure. Being a laboratory worker (OR: 148.4) or doctor (OR: 125.7) were the only predictors of vaccination uptake. Conclusion: There is need to increase knowledge of HCWs, vaccination availability, vaccination uptake, PEP, and reduce the exposures of HCWs.
Wilson, Garrick Kenardo. "Mechanism(s) of hepatitis C virus induced liver injury." Thesis, University of Birmingham, 2012. http://etheses.bham.ac.uk//id/eprint/3530/.
Повний текст джерелаSatekge, Mpho Margaret. "Knowledge, attitudes and practices regarding the prevention of hepatitis B virus infections, in final year college student nurses in Gauteng Province." Thesis, University of Limpopo (Medunsa Campus), 2010. http://hdl.handle.net/10386/236.
Повний текст джерелаIntroduction: Hepatitis B infection is a serious blood-borne disease caused by the hepatitis B virus (HBV) which attacks the liver, and is the leading cause of liver cancer and cirrhosis of the liver. HBV can be transmitted through exposure to infected blood and human secretions through needle stick / sharps injuries and splashes. Thus nurses are at high risk for HBV infection. The aim of the study: To investigate the knowledge, attitudes and practices (KAP) regarding the prevention of hepatitis B virus infections, in final year college student nurses in Gauteng province. Methods: A cross-sectional quantitative survey on 350 final year nursing students was conducted in three Gauteng province nursing colleges, using an anonymous self administered questionnaire with questions on knowledge, attitudes, and practices regarding HBV. The data were analysed using SPSS (statistical package for social science studies). Results: Of 350 questionnaires distributed, 312 student nurses returned completed forms (response rate: 89.14% [312/350]). The majority were females (86.8% [270/331]) and were below 31 years of age (30.1% [93/309]). The majority (87.6% [271/310]) had good knowledge of the causes and prevention of HBV. The unvaccinated respondents had fairly low positive attitudes, with a mean, mode and median score of 1 (possible score from -4 to +4). The majority (79% [244/310]) practiced good compliance with universal precautions of, and the majority (64.9% [202/311]) were vaccinated. College A displayed significantly higher knowledge (p<0.001), positive attitudes (p=0.001) and safer practices (p<0.001) than college B and C.
Schwarz, Anne-Katrin. "Defining the mechanism(s) of Hepatitis C virus (HCV) entry." Thesis, University of Birmingham, 2009. http://etheses.bham.ac.uk//id/eprint/475/.
Повний текст джерелаLukhwareni, Azwidowi. "Exploring the Impact of Human Immunodeficiency Virus on Hepatitis B Virus Diagnosis, Prevention and Control in Co-infected Adult South African Patients on Highly Active Antiretroviral Therapy." Thesis, University of Limpopo (Medunsa), 2008. http://hdl.handle.net/10386/242.
Повний текст джерелаBackground and Objectives: South Africa is one of the countries highly affected by human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Some drugs (e.g. lamivudine) used as part of combination antiretroviral regimens for HIV treatment have dual activity against HBV and HIV. Despite high infection rate with both viruses, routine screening for HBV before initiation of treatment for HIV is not yet a standard practice. This study undertook to investigate: (1) the burden of HBV co-infection in HIV-positive patients enrolling for highly active antiretroviral therapy (HAART) at Dr George Mukhari hospital, (2) the impact of anti-HBV containing HAART regimens on HBV during the management of HBV/HIV co-infected patients, (3) the co-evolution of HBV and HIV drug-resistant strains, and (4) the correlation of HBV genotypes with response to anti-HBV containing HAART regimens. Study Population and Methods: To investigate the burden of HBV/HIV co-infections, a cohort of 192 HIV patients who were candidates for ARV treatment at Dr George Mukhari hospital were studied by screening for HBV serological markers (HBsAg, anti-HBs and anti- HBc) (Elecsys 2010, Roche Diagnostics) and HBV DNA with an in-house nested PCR assay targeting HBV polymerase gene. Quantitation of HBV DNA positive samples was performed with Roche Cobas Taqman HBV test 48 assay. To investigate the impact of lamivudine-containing HAART regimens on HBV during the management of HBV/HIV co-infected patients, as well as the coevolution of HBV and HIV drug-resistant strains, a total of 78 patients were studied. HBV virological response against lamivudine containing-HAART regimens [1a (lamivudine, stavudine and efaverenz); 1b (lamivudine, stavudine and neviripine)] was measured (Cobas Taqman HBV test 48, Roche diagnostics). HBV direct sequencing targeting HBV polymerase gene was performed on all baseline samples (n=78) and additional samples collected at various time points (n = 45). Direct sequencing was also performed on 30 HIV baseline samples targeting the HIV reverse transcriptase and protease genes (Spectru-Medix SCE 2410 Genetic Analysis System and ABI PRISM® 3100 Genetic Analyzer version 3.7). To explore the genetic diversity of HBV and HIV strains circulating in Pretoria and surrounding areas, as well as the correlation of HBV genotypes with response to lamivudine-containing-HAART regimens in co-infected patients, all baseline and follow-up HBV and HIV sequences were analysed, compared and correlated with treatment. Sequence alignments and phylogenetic studies for both HBV and vi HIV were conducted with MAFFT, Mega 4 and neighbour joining phylogenetic trees generated with the PHYLIP programme. Results: Three significant findings were observed in this study. Firstly, the majority of South African HIV patients enrolling for HAART were exposed to HBV infection and either had acute or chronic HBV infections. A total of 63.0% of patients were found to have one or more HBV markers, with 40.6% having detectable HBV DNA as an indication of replication. The study also detected 22.9% with positive HBsAg, and 23% of 77% HBsAg-negative patients having occult hepatitis B infection. Secondly, HBV/HIV co-infected patients do benefit during the management of HIV infections with lamivudine-containing HAART regimens. A total of 68.4% of patients responded to HAART, with undetectable HBV DNA during 18 to 24 months of follow-up. A total of 91.3% of HIV patients also responded to HAART with an undetectable HIV viral load during 6 to 12 months of follow-up. However, a total of 18% of patients had persistent HBV DNA, yielding various HBV virological responses against lamivudine containing-HAART regimens. This proportion of patients poses a question regarding the management of HBV and HIV coinfections, as guidelines on the use of HAART with anti-HBV activity from developed countries, may not necessarily be followed in developing countries. The results further showed that baseline drug-resistance was more frequent with HIV than HBV in this cohort of patients. The following HIV primary drug resistant mutants were observed: nine major NRT's primary mutants, M41L (1/30), E44A (1/30), V75M (1/30), F77L (1/30), V118I (1/30), M184V (1/30), L210S (1/30), T215Y (1/30) and V90I (1/30), and five major NNRT’s primary mutants were also detected, K103N (3/30), Y318CFSY (1/30), E138Q (1/30), P225H (1/30) and K238T. However, all followup samples had undetectable HIV viral load. In contrast to HIV, only one patient was detected with HBV mutant, M204I, at baseline. The mutant reversed to wild type during 6 months and other follow-up (12, 18 and 24 months). Finally, this study indicated that the HBV genotype A is still the most prevalent genotype circulating in South Africa. Of the 78 HBV sequences, 77 were genotype A and 1 sequence was genotype G. This is the first report from Africa of the detection of HBV genotype G. HIV subtype C remains the predominant prevailing subtype in South Africa. HBV genotype or HIV subtype C was not observed to influence any treatment outcome following treatment with vii lamivudine-containing HAART regimens. The study also indicated that patients on lamivudinecontaining HAART regimens do benefit not only by suppressing HIV and HBV viral load, but also improving immunity (i.e. CD4 cells count increases). Conclusion: Overall, the present study highlights the need for screening HBV before initiation of any HAART containing anti-HBV regimens in HBV/HIV co-infected patients. It necessitates the use of molecular assays for effective laboratory in diagnosis of occult HBV infections in HIVpositive patients, especially in developing countries where these assays are not widely available. While lamivudine-containing HAART regimens do benefit both HBV and HIV patients in co-infected individuals, however, whether HBV virological response is temporary or sustained is unknown at this stage. What is certain is that these patients require an effective monitoring programme as (1) a small percentage experience variable HBV virological responses (partial, reactivation, or no response), and (2) hepatitic flares are likely to develop if HAART is terminated (e.g. by patient), or the current HAART regimen is switched to another regimen without anti-HBV activity. HBV genotype A remains the dominant genotype in South Africa, but novel genotypes can be detected. HIV subtype C was found to be the prevalent subtype. HBV genotype or HIV subtype C were not seen to influence any treatment outcome following treatment with lamivudine-containing HAART regimens. Recommendations: HIV patients should be screened for HBV before initiation of anti-HBV containing HAART regimens. The screening of HBV in HIV patients is also important since some drugs included as part of HAART (e.g. nevirapine) may cause hepatotoxicity and exacerbate HBV infections leading to increased morbidity and mortality due to liver complications. Immunization and immune boosters of HIV patients with low (< 10IU/L) or no immunity against HBV should be done as this could be beneficial, although these patients may not respond optimally, or their immunity may wane faster due to immunocompromised status. Monitoring of both HBV and HIV resistant strains should be conducted for timely detection for the occurrence of multiple resistant mutations, which could limit future therapeutic option for both viruses.
Hutchinson, Sharon J. "Modelling the hepatitis C virus disease burden among injecting drug users in Scotland." Thesis, University of Glasgow, 2004. http://theses.gla.ac.uk/1340/.
Повний текст джерелаStone, Jack Elliot. "Analysing the role of incarceration in the transmission and prevention of human immunodeficiency virus and hepatitis C virus amongst people who inject drugs." Thesis, University of Bristol, 2018. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.743044.
Повний текст джерелаКниги з теми "Hepatitis viruses Prevention"
1936-, Willson Richard A., ed. Viral hepatitis: Diagnosis, treatment, prevention. New York: M. Dekker, 1997.
Знайти повний текст джерелаYin, Guoyou. Yi xing gan yan fan zhi 30 fa. Beijing: Jin dun, 2002.
Знайти повний текст джерелаMayfield, Eleanor. Protecting patients and professionals from blood-borne disease. [Rockville, Md.] (5600 Fishers Lane, Rockville 20857): [Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Public Affairs, 1993.
Знайти повний текст джерелаMayfield, Eleanor. Protecting patients and professionals from blood-borne disease. [Rockville, Md.] (5600 Fishers Lane, Rockville 20857): [Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Public Affairs, 1993.
Знайти повний текст джерелаAdministration, United States Occupational Safety and Health. Enforcement procedures for occupational exposure to hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Washington, D.C: U.S. Dept. of Labor, Assistant Secretary for Occupational Safety and Health, 1990.
Знайти повний текст джерелаUnited States. Occupational Safety and Health Administration. Enforcement procedures for occupational exposure to hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Washington, D.C: U.S. Dept. of Labor, Assistant Secretary for Occupational Safety and Health, 1990.
Знайти повний текст джерелаGreat Britain. Expert Advisory Group on AIDS. Guidance for clinical health care workers: Protection against infection with HIV and hepatitis viruses. London: H.M.S.O., 1990.
Знайти повний текст джерелаUnited States. Occupational Safety and Health Administration. Enforcement procedures for the occupational exposure to Bloodborne Pathogens Standard, 29 CFR 1910.1030. Washington, D.C: U.S. Dept. of Labor, Assistant Secretary for Occupational Safety and Health, 1992.
Знайти повний текст джерелаUnited States. Congress. House. Committee on Education and Labor. Subcommittee on Health and Safety. Oversight hearings on OSHA's proposed standard to protect health care workers against blood-borne pathogens including the AIDS and hepatitis B viruses: Hearings before the Subcommittee on Health and Safety of the Committee on Education and Labor, House of Representatives, One Hundred First Congress, first session .... Washington: U.S. G.P.O., 1990.
Знайти повний текст джерелаUnited States. Congress. House. Committee on Education and Labor. Subcommittee on Health and Safety. Oversight hearings on OSHA's proposed standard to protect health care workers against blood-borne pathogens including the AIDS and hepatitis B viruses: Hearings before the Subcommittee on Health and Safety of the Committee on Education and Labor, House of Representatives, One Hundred First Congress, first session. Washington: U.S. G.P.O., 1990.
Знайти повний текст джерелаЧастини книг з теми "Hepatitis viruses Prevention"
Blatt, Lawrence M., and Myron Tong. "Epidemiology of chronic hepatitis viruses: hepatitis B virus and hepatitis C virus." In Hepatitis Prevention and Treatment, 29–38. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_2.
Повний текст джерелаChang, Mei-Hwei. "Prevention of Hepatitis B Virus Infection and Liver Cancer." In Viruses and Human Cancer, 71–90. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-57362-1_4.
Повний текст джерелаLim, E. J., and J. Torresi. "Prevention of Hepatitis C Virus Infection and Liver Cancer." In Viruses and Human Cancer, 107–40. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-57362-1_6.
Повний текст джерелаChang, Mei-Hwei. "Prevention of Hepatitis B Virus Infection and Liver Cancer." In Viruses and Human Cancer, 75–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-38965-8_5.
Повний текст джерелаLim, E. J., and J. Torresi. "Prevention of Hepatitis C Virus Infection and Liver Cancer." In Viruses and Human Cancer, 113–33. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-38965-8_7.
Повний текст джерелаMichalak, Tomasz I. "Immunology of hepatitis B virus." In Hepatitis Prevention and Treatment, 87–105. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_5.
Повний текст джерелаBarnes, Eleanor J., Nasser Semmo, and Paul Klenerman. "Immunology of hepatitis C virus." In Hepatitis Prevention and Treatment, 107–23. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_6.
Повний текст джерелаKurstak, Edouard. "Control and prevention of hepatitis B virus infection." In Viral Hepatitis, 128–48. Vienna: Springer Vienna, 1993. http://dx.doi.org/10.1007/978-3-7091-4437-4_16.
Повний текст джерелаCondreay, Lynn D., and Sarah A. Harris. "Molecular virology of hepatitis B virus." In Hepatitis Prevention and Treatment, 39–65. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_3.
Повний текст джерелаLuo, Guangxiang. "Molecular virology of hepatitis C virus." In Hepatitis Prevention and Treatment, 67–85. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7903-3_4.
Повний текст джерелаТези доповідей конференцій з теми "Hepatitis viruses Prevention"
Cox, Andrea L. "Abstract IA16: Prevention of hepatocellular carcinoma through preventative hepatitis C vaccination." In Abstracts: AACR Special Conference on the Microbiome, Viruses, and Cancer; February 21-24, 2020; Orlando, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.mvc2020-ia16.
Повний текст джерела"Knowledge, Attitude and Perception of Incomplete Hepatitis B Vaccination Among Staff of University College Hospital, Ibadan." In International Conference on Public Health and Humanitarian Action. International Federation of Medical Students' Associations - Jordan, 2022. http://dx.doi.org/10.56950/rfob4613.
Повний текст джерелаHuang, Jiaqi, Måns Magnusson, Anna Törner, Weimin Ye, and Ann-Sofi Duberg. "Abstract A07: Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: A nationwide study in Sweden." In Abstracts: Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; Oct 27-30, 2013; National Harbor, MD. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1940-6215.prev-13-a07.
Повний текст джерелаKumar, Vijay, Atish Mukherji, and Vaibhao Janbandhu. "Abstract B78: The X protein of hepatitis B virus induces PI3K/Akt pathway to overcome gentoxic stress-related cyclin D1 degradation and growth arrest." In Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-b78.
Повний текст джерелаLow, Jia Ming, and Guan-Huei Lee. "289 Knowledge and awareness of maternal chronic hepatitis carriers to perinatal antiviral use in prevention of mother-to-child hepatitis B virus transmission." In RCPCH Conference Singapore. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjpo-2021-rcpch.160.
Повний текст джерелаMiralles Andreu, G., M. Pomares Bernabeu, S. Gutiérrez Palomo, IP Jiménez Pulido, L. Soriano Irigaray, and A. Navarro Ruiz. "5PSQ-156 Compliance of recommendations for the prevention of hepatitis B virus reactivation during daratumumab treatment." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.275.
Повний текст джерелаCastro, Ana Rita Motta, Livia Lima, Larissa Bandeira, Selma Gomes, Barbara Lago, Grazielli Rezende, and Gabriela Alves Cesar. "Hepatitis B: changes in epidemiological features of Afrodescendant communities in Central Brazil." In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p142.
Повний текст джерелаWen, Chi‐Pang, Yen Chen Chang, Min Kwang Tsai, Hui Ting Chan, Isabella W. S. Chung, Ting Yuan David Cheng, Shan Pou Tsai, and Po‐Huang Chiang. "Abstract B135: Mortality risks and life‐shortening effect of hepatitis C virus infection: A prospective cohort study of 487,369 adults in Taiwan." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Dec 6–9, 2009; Houston, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-09-b135.
Повний текст джерелаShiota, Goshi, Hiroyuki Tsuchiya, Tomohiko Sakabe, and Yoshiko Hoshikawa. "Abstract 5723: A role of retinoic acid in preventive effect of hepatitis C virus- and oxidative stress-related hepatocarcinogenesis." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5723.
Повний текст джерелаMereu, Noemi Maria, Ilaria Pilia, Maria Francesca Piazza, Laura Spada, Alberto Lai, Igor Portoghese, Maura Galletta, Rosa Cristina Coppola, and Marcello Campagna. "P157 Pattern of hepatitis a virus epidemiology in nursing students and adherence to preventive measures at two training wards of a university hospital." In Occupational Health: Think Globally, Act Locally, EPICOH 2016, September 4–7, 2016, Barcelona, Spain. BMJ Publishing Group Ltd, 2016. http://dx.doi.org/10.1136/oemed-2016-103951.474.
Повний текст джерелаЗвіти організацій з теми "Hepatitis viruses Prevention"
A curriculum guide for public-safety and emergency-response workers. Prevention of transmission of human immunodeficiency virus and hepatitis B virus. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, February 1989. http://dx.doi.org/10.26616/nioshpub89108.
Повний текст джерела